Henry Schein, Inc. (NASDAQ:HSIC) COO Sells $918,000.00 in Stock

Henry Schein, Inc. (NASDAQ:HSIC) COO Michael S. Ettinger sold 12,240 shares of the company’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $75.00, for a total transaction of $918,000.00. Following the transaction, the chief operating officer now owns 87,706 shares of the company’s stock, valued at approximately $6,577,950. This represents a 12.25 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Henry Schein Stock Performance

Henry Schein stock opened at $75.08 on Friday. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.42 and a quick ratio of 0.82. The firm has a market capitalization of $9.36 billion, a P/E ratio of 30.90, a price-to-earnings-growth ratio of 2.15 and a beta of 0.87. Henry Schein, Inc. has a 1-year low of $63.67 and a 1-year high of $82.63. The company’s 50-day moving average is $70.80 and its 200 day moving average is $69.72.

Henry Schein (NASDAQ:HSIC) last released its earnings results on Tuesday, November 5th. The company reported $1.22 earnings per share for the quarter, topping the consensus estimate of $1.17 by $0.05. The business had revenue of $3.17 billion during the quarter, compared to the consensus estimate of $3.24 billion. Henry Schein had a return on equity of 12.90% and a net margin of 2.51%. The business’s revenue for the quarter was up .4% compared to the same quarter last year. During the same period last year, the company earned $1.32 earnings per share. Research analysts forecast that Henry Schein, Inc. will post 4.78 EPS for the current year.

Institutional Investors Weigh In On Henry Schein

Institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. raised its holdings in shares of Henry Schein by 1.7% in the first quarter. Vanguard Group Inc. now owns 15,432,001 shares of the company’s stock valued at $1,165,425,000 after acquiring an additional 260,537 shares in the last quarter. Covestor Ltd grew its stake in Henry Schein by 12.8% during the 1st quarter. Covestor Ltd now owns 1,511 shares of the company’s stock valued at $114,000 after purchasing an additional 171 shares during the last quarter. UniSuper Management Pty Ltd raised its stake in shares of Henry Schein by 611.8% in the first quarter. UniSuper Management Pty Ltd now owns 13,695 shares of the company’s stock worth $1,034,000 after purchasing an additional 11,771 shares during the last quarter. MQS Management LLC acquired a new stake in shares of Henry Schein during the first quarter worth about $399,000. Finally, Gamco Investors INC. ET AL boosted its position in Henry Schein by 16.4% in the first quarter. Gamco Investors INC. ET AL now owns 345,135 shares of the company’s stock valued at $26,065,000 after buying an additional 48,510 shares during the last quarter. 96.62% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have commented on HSIC shares. StockNews.com raised shares of Henry Schein from a “sell” rating to a “hold” rating in a report on Thursday, November 7th. UBS Group cut their price target on Henry Schein from $75.00 to $72.00 and set a “neutral” rating for the company in a report on Wednesday, August 7th. Evercore ISI upped their price objective on Henry Schein from $70.00 to $74.00 and gave the stock an “in-line” rating in a report on Tuesday, October 8th. Barrington Research restated an “outperform” rating and issued a $82.00 price target on shares of Henry Schein in a research report on Wednesday, November 6th. Finally, JPMorgan Chase & Co. lowered their price objective on shares of Henry Schein from $88.00 to $80.00 and set an “overweight” rating for the company in a research report on Monday, August 12th. Six analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $78.89.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.